It is a semi-synthetic broad-spectrum penicillin antibiotic that mainly acts on the bacterial reproduction stage by inhibiting the biosynthesis of cell wall mucopolypeptides. It is effective against many Gram-positive and Gram-negative bacteria.

It has a β-lactam structure similar to penicillin and has only weak antibacterial activity itself, but it can inactivate enzymes produced by many bacteria by blocking the active site of β-lactamase. It is especially effective against clinically important plasmid-mediated β-lactamases (these enzymes are usually associated with changes in resistance to penicillins and cephalosporins).

This product is a sulfonamide antibiotic that acts competitively with para-aminobenzoic acid (PABA) on dihydrofolate synthase in bacteria, inhibits the synthesis of bacterial folate, reduces the production of tetrahydrofolate, and thus inhibits bacterial growth and reproduction. It has antibacterial effects on gram-positive and gram-negative bacteria such as hemolytic streptococci, Neisseria meningitidis, and Staphylococcus.

This product is a broad-spectrum antibacterial agent, with bactericidal effect at high concentration. It has antibacterial effect on Streptococcus pneumoniae, hemolytic Streptococcus, Streptococcus viridans and some Staphylococci, Clostridium perfringens, Bacillus anthracis, Yersinia pestis, Corynebacterium diphtheriae, Clostridium tetani, Brucella, Haemophilus influenzae, Campylobacter, Vibrio cholerae, and also has inhibitory effect on Rickettsia, Mycoplasma, Chlamydia, Spirochete, and some protozoa. It has better effect on Gram-positive bacteria than Gram-negative bacteria. The drug can specifically bind to the A position of the 30S subunit of the bacterial ribosome, preventing the connection of aminoacyl-tRNA at this position, thereby inhibiting the growth of peptide chains and affecting the synthesis of bacterial proteins.

This product is a macrolide antibiotic, which has inhibitory effects on Gram-positive bacteria such as Staphylococcus aureus, Streptococcus, and Pneumococcus, as well as some Gram-negative bacteria such as Haemophilus influenzae, Bordetella pertussis, Neisseria gonorrhoeae, Legionella pneumophila, and some anaerobic bacteria such as Bacteroides fragilis, Streptococcus peptostreptococcus, and Propionibacterium acnes. In addition, it also has inhibitory effects on mycoplasma. The characteristics of this product are that its antibacterial activity in vitro is similar to that of erythromycin, but its antibacterial activity in vivo against some bacteria such as Staphylococcus aureus, Streptococcus, and Haemophilus influenzae is stronger than that of erythromycin. There is cross-resistance between this product and erythromycin. The mechanism of action of this product is to inhibit the association of the 50S subunit of the nuclear protein and inhibit protein synthesis to produce an antibacterial effect.